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1. General experimental details and procedures 
 
General: IR spectra were recorded with a Perkin-Elmer FTIR 1725X spectrophotometer. UV spectra were recorded with a GBC-
Cintra 40 UV-vis spectrophotometer. 1H and 13C NMR spectra were recorded with Varian Gemini 200 (1H at 200 MHz, 13C at 50 
MHz) and Bruker Avance spectrometers (1H at 500 MHz, 13C at 125 MHz). Chemical shifts are measured in ppm, J in Hz. Sample 
was dissolved in the indicated solvent system, and TMS was used as an internal reference. The high-resolution MS spectra were 
obtained with an Agilent Technologies 6210 TOF LC-MS spectrometer. Dry-column flash chromatography (DCFC) was carried 
out with Merck silica gel 60 (15-40µm). Thin layer chromatography (TLC) was carried out on precoated silica gel 60 F254 plates.  
HPTLC. All substances were chromatographed on HPTLC silica gel 60 aluminium sheets (Merck, 4.0 × 6.0 cm) as a stationary 
phase. Samples were applied by CAMAG Linomat 5 “linomat5_130827“ S/N 130827 (1.00.12) device. Spots were detected by 
CAMAG TLC Scanner 3 „Scanner3_131003“ S/N 131003 (1.14.26), at 340 nm. Software application winCATS Planar 
Chromatography Manager SN 1311W038, V1.4.2 was used for data processing. In addition, UV spectra of the spots were 
obtained by scanning from 200-700 nm. 
System toluene/ethyl-acetate 7:3 was used for HPTLC of bisadducts 7-9, while toluene/ethyl-acetate 1:1 was used for adducts 10-
14 as a mobile phase. 
Morphology investigations: Investigations of sample morphology were carried out with SEM, using a JEOL JSM-840A 
instrument, at an acceleration voltage of 30 kV. The samples for investigation of morphology of self-organized stuctures of 7-14 
were prepared by dissolving in differente solvents (ODCB, PhMe, CHCl3, PhMe/i-PrOH (1:1, v/v), PhMe/dioxane (1:1, v/v) at 
room temperature. A drop of 0.5 mM solution of fullerene derivative was deposited on the surface of a glass substrate (10x10 
mm) and left during 24 h to slowly evaporate in a glass Petri dish (diameter 10 cm) under PhMe atmosphere at room temperature 
(the exceptions were made in case of ODCB solutions, in which 2-3 days were necessary for total evaporation of the solvent). The 
investigated samples were gold sputtered in a JFC 1100 ion sputter device and then subjected to SEM observations. 
 
Electrochemical Measurements: The electrochemical behavior of C60 bis-adducts was investigated using 1mM solutions of 
bisadducts 7-13 and 15-19 and difullerene 14 in dry and degased mixture ODCB/DMF 2:1, and in DCM (only bisadducts 7-13), 
both containing 0.1 M TBAP as a supporting electrolyte. In order to remove oxigen from the electrolyte, the system was bubbled 
with argon prior to each experiment and argon atmosphere above the liquid surface was maintained during the scans. The 
electrochemical mesurements were carried out on CH1760b Electrochemical workstation potentiostat (CH Instruments, Austin, 
TX) using conventional three-electrode cell (5 mL) equipped with GCE (glassy carbon electrode), as a working, Ag/Ag+ (a silver 
wire in contact with 0.01 M AgNO3 and 0.10 M TBAP in acetonitrile) , as a reference and the platinum wire as a auxiliary 
electrodes, calibrated with a ferrocene/ferrocenyl couple (Fc/Fc+) as an internal standard. All experiments were performed at room 
temperature in the potential range of -2.5 to 0.5 V vs Ag/Ag+ (i.e. -3.0 to 0.0 V vs Fc/Fc+), at sweep rates between 0.01 and 1 V/s. 
All half-wave reduction potentials are presented in V vs Fc/Fc+ (measured E1/2 of Fc/Fc+: 0.552 and 0.674 V vs Ag/Ag+in DCM 
and ODCB/DMF 2:1, respectively). 
 
Antioxidant Activity in vitro: The antioxidant capacity was determined according to a published procedure with minor changes.  
Preparation of liposomal gel of fullerene C60 and fullerene derivatives 7-14 1. Liposomes were composed of tested compounds 
and soybean lecithin in 1:4 mass ratio. Measured fullerene or fullerene bisadduct (0.1-1 mg) and fourfold mass of lecithin are 
solubilized in minimal volume of PhMe under the ultrasound for 1 minute. Solvent was evaporated and film of lipid-fullerene 
complex carefully diluted on vortex with deionized water to the concentration of the fullerenic component of 0.02 mg/mL. The 
final concentration of the pure compound of 0.002 mg/mL was obtained prior to use mixing the solution with water in 1:9 ratio.  
                                                 
1 M. B. Lens, E. De Marni, R. Gullo,U. Citernesi and R. Crippa, WO 043074 A1, 2007. 
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 FOX reagent preparation2. Working FOX reagent was preared by adding 10 mL of Reagent 2 (98 mg of (NH4)2Fe(SO4)2x6H2O 
(FAS) in 100 mL of 250mM H2SO4) to 900 mL of Reagent 1 (95 mg of xylenol orange sodium salt (XO) and 880 mg of 2,6-di-t-
butyl-4-methylphenol (BHT) in 900 mL of MeOH) giving the final concentrations of 250 µM FAS, 125 µM of XO, 25 mM 
H2SO4, and 4 mM BHT. The reagent was consumed within 24 h. The apsorbance was measured at 560 nm by UV-vis 
spectrophotometer GBC-Cintra 40 with 90% MeOH as a zero probe.  
The applicability of the method in used range of peroxide concentration was confirmed by preparing standard calibration curve 
using increasing concentrations of peroxide (TBHP or H2O2; 0-200 µM) incubated with FOX reagent at room temperature for 30 
min. Absorbances measured at 560 nm at the different concentrations confirmed linear correlation.  
Sample preparation. The fullerenesomes and vitamin C solutions (0.02 mg/mL) were diluted by nine-fold volume of water to gain 
0.002 mg/mL concentration prior to use (0.050 mL : 0.450 mL of water). The same volume of 200 µM peroxide (obtained by 
diluting 0.050 mL of 2 mM peroxide with 0.450 mL of water) was added to the sample and vortexed for 1 min. After 10 min of 
incubation at room temperature, to an aliquot of 0.050 mL of the sample 0.950 mL of FOX reagent was added. Absorbance at 560 
nm was determined for each sample after 80 min. of incubation at room temperature.  
Standard probe preparation. The standard probe of peroxides were prepared by mixing the same volume of 200 µM peroxide 
(obtained by diluting 0.050 mL of 2 mM peroxide with 0.450 mL of water) and water. To a 0.050mL of mixture 0.950 mL of 
FOX reagent was added. The absorbance of the standard probe, determined after 80 min., reffers to the starting (maximum) 
concentration of the peroxide, prior to incubation. Difference of absorbances of the standard probe (As) and sample (A) is 
proportional to the quantity of the consumed peroxide by the sample compound. 
Blank probe preparation. The blank probe contained 0.950 mL of FOX reagent and 0.050 mL of water. Apsorbance of the blank 
probe  measured at 560 nm (A0) reffers to the color of the reagent itself in the absence of the peroxide, and all absorbances of the 
samples and standards are diminished by the value of A0 for the calculations of the peroxide concentration. 
All experiments were performed in triplicates, and the average values were taken. 
Antioxidative capacities were calculated according to formula (1): 
 
     Δ (%) = 100×(A-As)/(As-A0),     (1) 
 
where A0, As and A are apsorbance values determined at the same conditions for blank probe, standard peroxide solution and 
probe, respectively.  
The antioxidant activities relative to the equimolar concentration of vitamin C were calculated using the equation (2): 
     AOAmol vs vit C = (Δ/Δvit C)/(M/Mvit C)    (2) 
where Δ and Δvit C represent the direct antioxidant capacity of the tested compound and vitamin C, respectivelly and M and Mvit C 
their molecular weights. 
 
The antioxidant activities relative to the equimolar concentration of the fullerene C60 were calculated using the equation (3): 
     AOAmol vs C60 = (Δ/ΔC60)/(M/MC60)   (3) 
where Δ and ΔC60 represent the direct antioxidant capacity of the tested compound and the C60, respectivelly and M and MC60 their 
molecular weights. 
                                                 
2 S. Gao, M. Miller, X. Q. Han, EP 1593685 A1, 2005. 
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2. Synthesis of the compounds 3-63 
 
Dibenzyl-N,N'-(3,6-dioxaoctane-1,8-diyl)diglycinate (3). To an ice-cooled solution of diamine 1 (4.06 g, 4.00 mL, 0.027 mol, 1 
mol equiv) and TEA (5.53 g, 7.80 mL, 0.055 mol, 2 mol equiv) in DCM (160 mL), solution of BBA (12.6 g, 8.60 mL, 0.055 mol, 
2 mol equiv) in DCM (80 mL), was added dropwise, during 5h. After additional stirring for 24h, mixture was washed with H2O (3 
x100 mL) and then with brine (2 x100 mL), and dried over anh. Na2SO4. The solvent was removed in vacuo and the remaining 
material was purified on a SiO2 column by dry-flash chromatography. Dibenzyl-N,N'-(3,6-dioxaoctane-1,8-diyl)diglycinate (3) 
was isolated as a colourless oil (4.94 g, 41%) using EtOAc/MeOH 9:1 as an eluent. IR (ATR): ṽ/cm-1 3379, 3031, 2872, 1745, 
1665, 1456, 1353, 1198, 1117, 1023, 746, 702. NMR: δH (500 MHz, CDCl3, Me4Si): 7.34 (5H, s, CHAr); 5.15 (2H, s, CH2Bn); 3.61 
(2H, s, CH24); 3.61 (2H, t, J=5.0 Hz, CH22); 3.51 (2H, s, CH2Gly); 3.31 (1H, br s, NH); 2.83 ppm (2H, t, J=5.0 Hz, CH21). δC (125 
MHz, CDCl3, Me4Si): 171.88 (C=O); 135.49 (CqAr); 128.49; 128.28; and 128.25 (CHAr); 70.22 and 70.04 (CH22,4); 66.48 (CH2Bn); 
50.62 (CH2Gly); 48.63 ppm (CH21). HR-MS: m/z calc. for [C24H33N2O6+H]+: 445.23331, measured 445.23183; calc. for 
[C24H32N2O6+Na]+: 467.21526, measured 467.21342. 
Dibenzyl-N,N'-(4,7,10-trioxatridecane-1,13-diyl)diglycinate (4) To an ice-cooled solution of diamine 7 (4.02 g; 4.00 mL; 0.018 
mol; 1 mol equiv) and TEA (3.68 g; 5.04 mL; 0.036 mol; 2 mol equiv) in DCM (112 mL), solution of BBA (8.34 g; 5.72 ml; 
0.036 mol; 2 mol equiv) in DCM (56 mL), was added dropwise, during 6h. After additional stirring for 20h, mixture was washed 
with H2O (3 x100 mL) and then with brine (2 x100 mL), and dried over anh. Na2SO4. The solvent was removed in vacuo and the 
remaining material was purified on a SiO2 column by dry-flash chromatography. Dibenzyl-N,N'-(4,7,10-trioxatridecane-1,13-
diyl)diglycinate (4) was isolated as a colourless oil (1.54 g, 33%) using EtOAc/MeOH 4:1 as an eluent. IR (ATR): ṽ/cm-1 3340, 
3063, 3033, 2941, 2868, 1742, 1458, 1350, 1212, 1184, 1150, 968, 750, 701. NMR: δH (200 MHz, CDCl3, Me4Si) 7.35 (s, 5H, 
CHAr); 5.16 (s, 2H, CH2Bn ); 3.68-3.48 (m, 6H, CH23,5,6); 3.44 (s, 2H, CH2Gly); 2.69 (t, J=6.6 Hz, 2H, CH21); 1.86 (s, 1H, NH); 1.77 
ppm (quint, J=6.6 Hz, 2H, CH22). δC (50 MHz, CDCl3, Me4Si) 172.33 (C=O), 135.59 (CqAr), 128.53; 128.29 (CHAr), 70.50; 70.10 
(CH25,6), 69.52 (CH23), 66.38 (CH2Bn),  50.91 (CH2Gly), 46.81 (CH21), 29.86 ppm (CH22). HR-MS: m/z calc. for 
[C28H42N2O7+2H]2+: 259.14905, measured 259.14980; calc. for [C28H40N2O7+Na]+: 539.27277, measured 539.27333; calc. for 
[C28H41N2O7+H]+: 517.29083, measured 517.29112. 
N,N'-(3,6-dioxaoctane-1,8-diyl)diglycine (5). To a solution of dibenzyl ester 3 (1.61 g; 3.622 mmol, MeOH 100 mL) 5% Pd/C 
was added (161 mg) and suspension was bubbled with argon. Mixture was hydrogenated at 40 psi for 20 h. After filtering the 
catalyst and evaporating the solvent, crude diacid 5 was isolated as colorless oil (940 mg; 98%). It was characterized 
spectroscopicaly and used for cycloaddition reaction without further purification. IR (ATR): ṽ/cm-1 3093, 2955, 2890, 1626, 1573, 
1462, 1417, 1371, 1310, 1242, 1211, 1118, 1085, 868, 600, 563. NMR: δH (500 MHz, CD3OD, Me4Si) 3.82 (t, J=5.0 Hz, 2H, 
CH22); 3.73 (s, 2H, CH24); 3.61 (s, 2H, CH2Gly); 3.29 (t, J=5.0 Hz, 2H, CH21) ppm. δC (125 MHz, CD3OD, Me4Si) 171.54 (C=O); 
71.13 (CH24); 66.95 (CH22); 50.43 (CH2Gly); 48.16 (CH21) ppm. HR-MS: m/z calc. for [C10H21N2O6+H]+: 265.13941, measured 
265.13866; calc.for [C10H20N2O6+Na]+: 287.12136, measured 287.11965. 
N,N'-(4,7,10-trioxatridecane-1,13-diyl)diglycine (6). To a solution of dibenzyl ester 4 (840 mg; 1.626 mmol , MeOH 100 mL) 
5% Pd/C was added (85 mg) and suspension was bubbled with argon. Mixture was hydrogenated at 40 psi for 20 h. After filtering 
the catalyst and evaporating the solvent, crude diacid 6 was isolated as a colorless oil (530 mg; 97 %). IR (ATR): ṽ/cm-1 3315, 
3064, 2926, 2874, 1740, 1620, 1600, 1454, 1395, 1324, 1243, 1208, 1134, 733, 697. NMR: δH (500 MHz, CD3OD, Me4Si) 3.69-
3.61 (m, 6H,CH23,5,6); 3.52 (s, 2H, CH2Gly); 3.18 (t, J=5.0 Hz, 2H, CH21); 1.98 ppm (quint, J=6.0, 2H, CH22 ). δC (125 MHz, 
CD3OD, Me4Si) 171.28 (C=O); 71.50 (CH25,6); 70.73 (CH23); 50.98 (CH2Gly); 48.32 (CH21); 27.23 ppm (CH22). HR-MS: m/z calc. 
for [C14H30N2O7+2H]2+: 169.10210, measured 169.10168; calc. for [C14H29N2O7+H]+: 337.19693, measured 337.19538; calc. for 
[C14H28N2O7+Na]+: 359.17887, measured 359.17724. 
                                                 
3 T. Kop , M. Bjelaković and D. Milić, Tetrahedron, 2015, 71, 4801-4809. 
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3. Synthesis of the fulleropyrrolidines 7-143 
 
Bisadducts 7-9. A suspension of C60 (545 mg; 0.757 mmol; 1 mol equiv), diglycine 5 (200 mg; 0.757 mmol; 1 mol equiv) and 
HCHO (230 mg; 7.570 mmol; 10 mol equiv) in ODCB (150 mL) was maintained at 160oC during 4 h. The obtained reaction 
mixture was cooled to room temperature, mixed with the same volume of hexane, deposited directly on the top of the SiO2 column 
(to remove solvent without further heating) and separated by dry-flash column chromatography. Elution with toluene yielded 
unreacted C60 (220 mg; 40.4%). Bisadducts (187.7 mg; 27.0 %) were eluted by listed eluents: bisadduct 7 (cis-1, 17.3 mg; 2.5%) 
was eluted with PhMe/EtOAc 7:3, bisadduct 8 (cis-2; 124.6 mg; 17.9%) with PhMe/EtOAc 6:4 and bisadduct 9 (cis-3; 45.8 mg; 
6.6 %) with PhMe/EtOAc 1:1. All products were purified by precipitation with MeOH from highly concentrated CS2/DCM 
solutions.  
Bisadduct 7 (cis-1): Rf=0.52 (PhMe/EtOAc 1:1); UV/Vis: λmax(PhMe)/nm 330 (ε/ mol-1dm3cm-1 30000), 402 (7000), 427 (6000), 
622 (210), 654 (200), 684 (160), 722 (160). IR (ATR) ṽ/cm-1 2923, 2851, 2785, 2334, 2024, 1505, 1453, 1427, 1334, 1304, 1203, 
1150, 1115, 964, 757. NMR: δH (500 MHz, CDCl3, Me4Si) 4.80 (d, J=10.0 Hz, 2H, CHpyrr); 4.47 (d, J=8.5 Hz 2H, CHpyrr); 4.01 
(d, J=8.0 Hz, 2H, CHpyrr); 4.00-3.92 (m, 4H, CH22,7), 3.88-3.82 (m, 2H, CH24,5); 3.82-3.76 (m, 2H, CH24’,5’); 3.52 (d, J=10.0 Hz, 
2H, CHpyrr); 3.38 (ddd, J=3.0; 7.0; 13.5 Hz; 2H, CH1,8); 3.11 (ddd, J=3.0; 5.5; 14.0 Hz; 2H, CH1',8’) ppm. δC (125 MHz, CDCl3, 
Me4Si) 151.96 (2C); 151.15 (2C); 150.58 (2C); 148.79 (2C); 147.87 (2C); 147. 08 (2C); 146.82 (2C); 146.20 (2C); 145.96 (2C); 
145.92 (1C); 145.37 (2C); 145.18 (2C); 144.89 (2C); 144.84 (2C); 144.42 (2C); 144.11(2C); 143.88 (2C); 143.79 (2C); 143.59 
(2C); 142.87 (2C); 142.55 (1C); 142.30 (2C); 142.24 (1C); 142.17 (2C); 141.82 (2C); 141.58 (2C); 140.61 (2C); 137.85 (1C); 
135.08 (2C); 134.89 (2C); 69.46 (C4,5); 68.63 (C2,7); 67.59 (2sp3-Cfull); 66.42 (2CHpyrr); 66.16 (2sp3-Cfull); 66.06 (2CHpyrr); 52.91 
ppm (C1,8). HR-MS: m/z calc. for [C70H20N2O2+H]+: 921.15975, measured 921.15538.  
Bisadduct 8 (cis-2): Rf=0.43 (PhMe/EtOAc 1:1); UV/Vis: λmax (PhMe)/nm 310 (ε/ mol-1dm3cm-1 40000); 374 (4900); 448 (4800); 
487 (3000); 572 (910); 647 (430); 680 (280). IR(ATR): ṽ/cm-1 2930, 2880, 2852, 2808, 2771, 1509, 1457, 1425, 1347, 1314, 1179, 
1129, 1110, 1081, 973, 733, 526. NMR: δH (500 MHz, CDCl3, Me4Si) 5.34 (dd, J=10.0; 2.0 Hz, 2H, CHpyrr), 4.27 (dd, J=9.0; 2.0 
Hz, 2H, CHpyrr); 4.02 (ddd, J=2.5; 8.0; 9.5 Hz; 2H, CH2,7); 3.90-3.80 (m, 6H, CH22’,7’,4,5); 3.64 (d, J=9.0 Hz; 2H, CHpyrr); 3.52 
(ddd, J=2.5; 5.5; 13.0 Hz; 2H, CH1,8); 3.32 (d, J=10.0 Hz, 2H, CHpyrr); 2.83 ppm (ddd, J=2.0, 8.0; 13.0 Hz; 2H, CH1’,8’). δC (125 
MHz, CDCl3, Me4Si) 159.83 (2C); 155.61 (2C); 149.12 (2C); 148.80 (1C); 148.72 (1C); 148.56 (1C); 147.49 (2C); 147.18 (2C); 
147.04 (2C); 146.72 (2C); 146.58 (2C); 146.23 (2C); 146.18 (2C); 146.00 (2C); 145.74 (2C); 145.37 (2C); 145.18 (2C); 145.08 
(2C); 144.60 (2C); 144.57 (2C); 144.26 (2C); 143.94 (2C); 143.81 (2C); 143.01 (2C); 141.51 (2C); 140.71 (2C); 139.05 (2C); 
133.53 (2C); 132.89 (2C); 129.49 (1C); 71.88 (C2,7); 70.38 (C4,5); 68.50 (2CHpyrr); 68.48 (2CHpyrr); 67.78 (2sp3-Cfull); 67.74 (2sp3-
Cfull); 52.55 ppm (C1,8). HR-MS: m/z calc. for [C70H20N2O2+H]+: 921.15975; measured 921.16010.  
Bisadduct 9 (cis-3): Rf=0.17 (PhMe/EtOAc 1:1); Rf=0.48 (PhMe/MeOH 4:1); UV/Vis: λmax (PhMe)/nm 300 (ε/ mol-1dm3cm-1 
47000); 331 (31000); 391 (11000); 431 (2900); 467 (2000); 548 (800); 657 (360); 732 (280). IR (ATR): ṽ/cm-1  2916, 2859, 2772, 
1676, 1451, 1427, 1341, 1305, 1274, 1112, 965, 759, 521. NMR: δH (500 MHz, CDCl3, Me4Si) 4.68 (dd, J=9.5; 2.0 Hz, 2H, 
CHpyrr); 4.47 (dd, J=9.0; J=2.0 Hz, 2H, CHpyrr); 4.08 (d, J=9.0 Hz, 2H, CHpyrr); 3.93-3.90 (m, 2H, CH4,5); 3.90-3.83 (m, 4H, 
CH22,7); 3.83-3.78 (m, 2H, CH4’,5’); 3.71 (ddd, 12.5; 9.5; 5.0 Hz; 2H, CH1,8); 3.49 (d, J=9.5 Hz, 2H, CHpyrr); 2.85 ppm (dt, J=12.5; 
4.0 Hz, 2H, CH1',8’). δC (125 MHz, CDCl3, Me4Si) 153.95 (2C); 149.64 (2C); 149.05 (2C); 148.55 (2C); 148.23 (2C); 148.22 
(2C); 147.77 (2C); 146.90 (2C); 146.59 (2C); 146.23 (2C); 146.05 (2C); 145.93 (2C); 145.70 (2C); 145.66 (2C); 145.10 (2C); 
144.91 (2C); 144.71 (2C); 142.16 (2C); 142.12 (4C); 142.06 (2C); 141.70 (2C); 139.74 (2C); 138.21 (2C); 137.07 (2C); 135.36 
(2C); 134.64 (2C); 130.26 (2C); 70.87 (C4,5); 70.36 (2sp3-Cfull); 69.41 (C2,7); 69.09 (2CH2pyrr); 66.44 (2sp3-Cfull); 65.72 (2CH2pyrr); 
52.28 ppm (C1,8). HR-MS: m/z calc. for [C70H20N2O2+H]+: 921.15975, measured 921.15997. 
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Compounds 10-14. A suspension of diacid 6 (255 mg; 0.757 mmol; 1 mol equiv), C60 (545 mg; 0.757 mmol; 1 mol equiv) and 
HCHO (230 mg; 7.57 mmol; 10 mol equiv) in ODCB (150 ml) was maintained at 160oC during 4 h. The obtained reaction 
mixture was cooled to room temperature, mixed with the same volume of hexane, deposited directly on the top of the SiO2 column 
(to remove solvent without further heating) and separated by dry-flash column chromatography (DFC). DFC yielded: C60 (300 
mg; 54.5%; eluent: toluene) difullerene 14 (20.5 mg; 3.2%; eluent: PhMe/EtOAc 8:2) and bisadducts (total yield 194.6 mg; 24.8 
%): bisadduct 10 (cis-1; 18.9 mg; 2.5%), eluted with PhMe/EtOAc 7:3, bisadduct 13 (eq; 24.7 mg; 3.3%), eluted with 
PhMe/EtOAc 6:4, bisadduct 12 (cis-3, 60.5 mg; 7.0 %), eluted with PhMe/EtOAc 1:1 and bisadduct 11 (cis-2; 90.5 mg; 12.0 %) 
eluted also with PhMe/EtOAc 1:1. All products were purified by precipitation with MeOH from highly concentrated DCM 
solutions.  
Bisadduct 10 (cis-1): Rf=0.46 (PhMe/EtOAc 1:1). UV/Vis: λmax(PhMe)/nm 328 (ε/ mol-1dm3cm-1 32000); 406 (7000); 430 (5900); 
623 (200); 651 (170); 676 (140); 710 (140). IR (ATR): ṽ/cm-1 2944, 2870, 2810, 1466, 1426, 1355, 1169, 1124, 735. NMR: δH 
(500 MHz, CDCl3, Me4Si) 4.28 (d, J=9.5 Hz, 2H, CHpyrr); 4.26 (d, J=8.5 Hz, 2H, CHpyrr); 4.04 (d, J=8.5 Hz, 2H, CHpyrr); 3.98 
(ddd, J=5.0; 8.0; 10.0 Hz; 2H, CH3,11); 3.86-3.76 (m, 10H, CH3',11’, 4CH2-O); 3.66 (d, J=9.5 Hz, 2H, CHpyrr); 3.23 (ddd, J= 7.0; 
8.0; 11.5 Hz; 2H, CH1,13); 2.98 (ddd, J=5.5; 8.5; 12.0 Hz; 2H, CH1',13’); 2.23-2.07 ppm (m, 4H, CH22,12). δC (125 MHz, CDCl3, 
Me4Si) 151.90 (2C); 151.06 (2C); 150.19 (2C); 148.93 (2C); 148.05 (2C); 147. 24 (2C); 146.99 (2C); 146.34 (2C); 146.09 (2C); 
145.91 (1C); 145.43 (2C); 145.34 (2C); 145.00 (4C); 144.57 (2C); 144.22 (2C); 144.04 (2C); 143.96 (2C); 143.72 (2C); 143.00 
(2C); 142.69 (1C); 142.43 (2C); 142.34 (1C); 142.30 (2C); 141.91 (2C); 141.56 (2C); 140.77 (2C); 137.94 (1C); 135.24 (2C); 
135.06 (2C), 70.91 (C-O); 70.22 (C-O); 69.34 (C3,11); 68.46 (2CH2pyrr); 68.10 (2sp3-Cfull); 66.59 (2CH2pyrr); 65.73 (2sp3-Cfull); 
52.47 (C1,13); 28.87 ppm (C2,12). HR-MS: m/z calc. for [C74H29N2O3+H]+: 993.21727, measured 993.21561.  
Bisadduct 11 (cis-2): Rf=0.16 (PhMe/EtOAc 1:1); Rf=0.46 (PhMe/MeOH 4:1). UV/Vis: λmax(PhMe)/nm 310 (ε/mol-1dm3cm-1 
43000); 375 (5300); 448 (5100); 483 (3000); 578 (900); 643 (420); 679 (280). IR(ATR): ṽ/cm-1 2879, 2775, 1452, 1345, 1244, 
1120, 1093, 914, 724, 526. NMR: δH (500 MHz, CDCl3, Me4Si) 4.01 (d, J=9.0 Hz; 2H, CHpyrr); 3.96 (d, J=9.0 Hz; 2H, CHpyrr); 
3.93 (d, J=9.5 Hz; 2H, CHpyrr); 3.83-3.75 (m, 4H, CH23,11); 3.81 (d, J=9.5 Hz; 2H, CHpyrr); 3.81-3.70 (m, 4H, 2CH2-O); 3.72-3.67 
(m, 4H, 2CH2-O) 3.16 (dt, J=12.0; 7.0 Hz; 2H, CH1,13); 2.90 (dt, J=12.0; 6.0 Hz; 2H, CH1’,13’); 2.07 ppm (quint, J=5.5 Hz; 4H, 
CH22,12). δC (125 MHz, CDCl3, Me4Si) 159.01 (2C); 156.41 (2C); 149.27 (2C); 148.86 (1C); 148.78 (1C); 148.27 (1C), 147.93 
(2C); 147.64 (2C); 147.51 (2C); 147.05 (2C); 146.89 (2C); 146.46 (2C); 146.11 (2C), 145.71 (2C); 145.70 (2C); 145.65 (2C); 
145.34 (2C); 145.15 (2C); 144.83 (2C); 144.57 (2C); 144.43 (2C); 144.18 (2C); 144.01 (2C); 142.98 (2C); 141.63 (2C); 140.94 
(2C); 138.86 (2C); 133.79 (2C); 133.05 (2C); 129.18 (1C); 70.69 (C-O); 70.58 (C-O); 68.76 (C3,11); 68.22 (2CHpyrr); 67.43 
(2CHpyrr); 67.35 (2sp3-Cfull); 67.07 (2sp3-Cfull); 50.96 (C1,13); 28.69 ppm (C2,12). HR-MS: m/z calc. for [C74H29N2O3+H]+: 
993.21727, measured 993.21682.  
Bisadduct 12 (cis-3): Rf=0.34 (PhMe/EtOAc 1:1). UV/Vis: λmax(PhMe)/nm 299 (ε/ mol-1dm3cm-1 49000); 330 (34000); 398 
(9600), 435 (3900); 464 (2600); 551 (1400); 640 (470); 729 (320). IR(ATR): ṽ/cm-1 2944, 2864, 2801, 2778, 1455, 1343, 1120, 
767, 526. NMR: δH (500 MHz, CDCl3, Me4Si) 4.36 (dd, J=9.0; 1.5 Hz; 2H, CHpyrr); 4.28 (dd, J=9.5; 1.5 Hz, 2H, CHpyrr); 3.90-
3.84 (m, 2H, CH3,11); 3.85-3.75 (m, 8H, 4CH2-O); 3.78 (d, J=9.0 Hz, 2H, CHpyrr); 3.70 (dt, J=10.0; 5.5 Hz; 2H, CH3’,11’); 3.61 (d, 
J=9.5 Hz, 2H, CHpyrr); 3.25 (dt, J=12.0; 7.0 Hz; 2H, CH1,13); 2.81 (dt, J=12.0; 6.0 Hz; 2H, CH1’,13’); 2.11-1.99 ppm (m, 4H, 
CH22,12). δC (125 MHz, CDCl3, Me4Si) 153.49(2C); 149.79(2C); 149.09(2C); 148.61(2C); 148.29(2C); 148.08(2C); 147.78(2C); 
147.03(2C); 146.26(2C); 146.15(2C); 146.12(2C); 145.98(2C); 145.76(2C); 145.62(2C); 145.18(2C); 144.98(2C); 144.85(2C); 
142.16 (4C); 142.13 (2C); 142.07 (2C); 141.65(2C); 139.79(2C); 138.37(2C); 137.11 (2C); 135.10(2C); 134.05(2C); 130.49(2C); 
71.09 (C-O); 70.58 (C-O); 69.69 (2sp3-Cfull); 69.11 (2CH2pyrr); 68.29 (C3,11); 67.33 (2CH2pyrr); 65.66 (2sp3-Cfull); 50.06 (C1,13); 
28.40 ppm (C2,12). HR-MS: m/z calc. for [C74H29N2O3+H]+: 993.21727; measured 993.21515.  
Bisadduct 13 (eq): Rf=0.36 (PhMe/EtOAc 1:1); UV/Vis: λmax(PhMe)/nm 319 (ε/ mol-1dm3cm-1 42000); 399 (6700); 423 (6100); 
456 (5900); 553 (1300); 584 (980); 627 (410); 710 (100). IR(ATR): ṽ/cm-1 3048, 2947, 2870, 2804, 1677, 1474, 1345, 1235, 
1175, 1126, 771, 738, 529. NMR: δH (500 MHz, CDCl3, Me4Si) 4.42 (dd, J=9.0; 1.0 Hz, 2H, CHpyrr-2); 4.11 (s, 2H, CH2pyrr-1); 
4.04 (s, 2H, CH2pyrr-1); 3.80 (dd, J=9.0; 1.0 Hz, 2H, CHpyrr-2); 3.81-3.77 (m, 2H, CH23); 3.78 (t, J=6.0; 2H, CH211); 3.68 (dd, J=7.0; 
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6.5 Hz; 2H, CH2-O); 3.64-3.61 (m, 2H, CH2-O); 3.53 (dd, J=7.5; 6.0, 2H, CH2-O); 3.51-3.48 (m, 2H, CH2-O); 3.10 (t, J=6.0 Hz; 
2H, CH213); 3.08 (t, J=6.0 Hz; 2H, CH21); 2.04 (quint, J=6.0 Hz; 2H, CH212), 1.98 (quint, J=6.0 Hz; 2H, CH22) ppm. δC (125 
MHz, CDCl3, Me4Si) 159.39 (2C); 154.59 (2C); 153.72 (2C); 152.72 (2C); 149.67 (1C); 148.84 (2C); 148.10 (2C); 147.71 (1C); 
147.54 (2C); 147.44 (2C); 147.37 (2C); 147.17 (2C); 146.02 (2C); 145.77 (2C); 145.15 (2C); 145.03 (2C); 144.69 (2C); 144.62 
(2C); 144.40 (2C); 143.54 (2C); 143.33 (2C); 142.30 (2C); 141.59 (2C); 141.42 (2C); 141.26 (2C); 140.89 (2C); 138.96 (2C); 
136.73 (2C); 135.54 (2C), 70.75 (2sp3-Cfull(pyrr-2)), 70.54 (C-O),70.32 (sp3-Cfull(pyrr-1)), 70.27 (C-O), 69.98 (sp3-Cfull(pyrr-1)), 69.83 
(C-O), 69.63 (C-O), 68.97 (C3), 68.56 (C11), 68.24 (CH2pyrr-1); 67.27 (2CH2pyrr-2); 66.70 (CH2pyrr-1); 50.75 (C13); 50.22 (C1); 29.22 
(C12); 28.47 ppm (C2). HR-MS: m/z: calc. for [C74H29N2O3+H]+: 993.21727, measured 993.21577. 
1,13-Bis(N-fulleropyrrolidino)-4,7,10-trioxatridecane (14): Rf=0.73 (PhMe/EtOAc 1:1); UV/Vis: λmax(PhMe)/nm 330 (ε/ mol-
1dm3cm-1 39000); 431 (3800); 546 (2100); 610 (1300); 698 (560). IR(KBr): ṽ/cm-1  2854, 2771, 1731, 1638, 1456, 1423, 1340, 
1301, 1232, 1108, 1039, 877, 766, 730, 524. NMR: δH (500 MHz, CDCl3+CS2, Me4Si) 4.41 (s, 8H, CH2pyrr); 3.86 (t, J=6.5 Hz, 
4H, CH23,11); 3.77 (br s, 8H, 4CH2-O); 3.21 (t, J=7.0 Hz, 4H, CH21,13); 2.23 ppm (quint, J=6.5 Hz; 4H, CH22,12). δC (125 MHz, 
CDCl3+CS2, Me4Si): 154.91 (8C); 147.18 (4C); 146.14 (8C); 145.95 (16C); 145.57 (4C); 145.33 (8C); 145.18 (8C); 144.46 (8C); 
143.01 (4C); 142.54 (8C); 142.14 (8C); 141.97 (8C); 141.79 (8C); 140.08 (8C); 136.15 (8C); 70.80 (2C-O); 70.58 (4sp3-Cfull); 
70.50 (2C-O); 69.31 (C3,11); 67.89 (4CH2pyrr); 51.64 (C1,13); 29.12 ppm (C2,12). HR-MS: m/z calc. for [C134H29N2O3+H]+: 
1713.21727, measured 1713.25252. 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Table S1. Visible region absorption bands 400–800 nm of bisadduct isomers.  
Regioizomer λ1 /ε λ2 /ε λ 3 /ε λ 4 /ε λ 5 /ε 
7 cis-1 402 /7000 427 /6000 654 /200 684 /160 722 /160 
10 cis-1 406 /7000 430 /5900 651 /170 676 /140 710 /140 
8 cis-2 448 /4800 487 /3000 572 /910 647 /430 680 /280 
11 cis-2 448 /5100 483 /3000 578 /900 643 /420 679 /280 
9 cis-3 431 /2900 467 /2000 548 /800 657 /360 732 /280 
12 cis-3 435 /3900 464 /2600 551 /1400 640 /470 729 /320 
13 eq 423 /6100 456 /5900 553 /1300 627 /410  710 /100 
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5. Table S2 13C NMR chemical shifts of the fullerene moiety of the bridged bisadducts. 
   
cis-1  cis-2  cis-3  eq 
-C6O2- -C10O3- -C6O2- -C10O3- -C6O2- -C10O3- -C10O3- 
151.96 151.90 159.83 159.01 153.95 153.49 159.39 
151.15 151.06 155.61 156.41 149.64 149.79 154.59 
150.58 150.19 149.12 149.27 149.05 149.09 153.72 
148.79 148.93 148.80* 148.86* 148.55 148.61 152.72 
147.87 148.05 148.72* 148.78* 148.23 148.29 149.67* 
147.08 147.24 148.56* 148.27* 148.22 148.08 148.84 
146.82 146.99 147.49 147.93 147.77 147.78 148.10 
146.20 146.34 147.18 147.64 146.90 147.03 147.71* 
145.96 146.09 147.04 147.51 146.59 146.26 147.54 
145.92* 145.91* 146.72 147.05 146.23 146.15 147.44 
145.37 145.43 146.58 146.89 146.05 146.12 147.37 
145.18 145.34 146.23 146.46 145.93 145.98 147.17 
144.89 146.18 146.11 145.70 145.76 146.02 
144.84 
145.00** 
146.00 145.71 145.66 145.62 145.77 
144.42 144.57 145.74 145.70 145.10 145.18 145.15 
144.11 144.22 145.37 145.65 144.91 144.98 145.03 
143.88 144.04 145.18 145.34 144.71 144.85 144.69 
143.79 143.96 145.08 145.15 142.16 144.62 
143.59 143.72 144.60 144.83 
142.16** 
144.40 
142.87 143.00 144.57 144.57 
142.12** 
142.13 143.54 
142.55* 142.69* 144.26 144.43 142.06 142.07 143.33 
142.30 142.43 143.94 144.18 141.70 141.65 142.30 
142.24* 142.34* 143.81 144.01 139.74 139.79 141.59 
142.17 142.30 143.01 142.98 138.21 138.37 141.42 
141.82 141.91 141.51 141.63 137.07 137.11 141.26 
141.58 141.56 140.71 140.94 135.36 135.10 140.89 
140.61 140.77 139.05 138.86 134.64 134.05 138.96 
137.85* 137.94* 133.53 133.79 130.26 130.49 136.73 
135.08 135.24 132.89 133.05   135.54 
134.89 135.06 129.49* 129.18*    
* Carbon peaks of relative intensity 1. 
** Carbon peaks of relative intensity 4 (the others of relative intensity 2). 
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6. Table S3 1H NMR and 13C NMR chemical shifts of the non-fullerene moiety of the bridged bisadducts. 
 
 δ(sp3-
Cfull) 
δ(CH2pyrr) δ (CH2tether) 
cis-1 (7) 
 
67.59 
66.16 
4.80d(10.0); 3.52d(10.0); 66.06 
4.47d(8.5); 4.01d(8.0); 66.42 
 
CH2(1,8) - 3.11ddd(3.0; 5.5; 14.0); 3.38ddd(3.0; 7.0; 
13.5); 52.91 
CH2(2,7) – 4.00-3.92m; 68.63 
CH2(4,5) - 3.88-3.82m; 3.82-3.76m; 69.46 
cis-2 (8) 
 
 
67.78 
67.74 
5.34dd(10.0; 2.0); 3.32d(10.0); 68.48 
4.27dd(9.0; 2.0); 3.64d(9.0); 68.50 
 
CH2(1,8) - 2.83ddd(2.0; 8.0; 13.0); 3.52ddd(2.5; 5.5; 
13.0); 52.55 
CH2(2,7) - 4.02ddd(2.5; 8.0; 9.5); 3.80-3.90m; 71.88 
CH2(4,5) - 3.80-3.90m; 70.38 
cis-3 (9) 
 
 
70.36 
66.44 
4.68dd(9.5; 2.0); 3.49d(9.5); 65.72; 
4.47dd(9.0; 2.0); 4.08d(9.0); 69.09 
 
CH2(1,8) - 2.85dt(12.5; 4.0); 3.71ddd(12.5; 9.5; 5.0); 
52.28 
CH2(2,7) - 3.83-3.90m; 69.41 
CH2(4,5) - 3.93-3.90m; 3.78-3.83m; 70.87 
cis-1 (10) 
 
 
68.10 
65.73 
4.28d(9.5); 3.66d(9.5); 68.46; 
4.26d(8.5); 4.04d(8.5); 66.59 
 
CH2(1,13) - 3.23ddd(7.0; 8.0; 11.5); 2.98ddd(5.5; 8.5; 
12.0); 52.47  
CH2(2,12) - 2.07-2.23m; 28.87 
CH2(3,11) - 3.98ddd(5.0; 8.0; 10.0); 3.76-3.86m; 
69.34 
CH2-O - 3.76-3.86m; 70.91 
CH2-O - 3.76-3.86m; 70.22 
cis-2 (11) 
 
 
67.35 
67.07 
4.01d(9.0); 3.96d(9.0); 67.43; 
3.93d(9.5); 3.81d(9.5); 68.22  
 
 
CH2(1,13) - 2.90dt(12.0; 6.0); 3.16dt(12.0; 7.0); 
50.96 
CH2(2,12) - 2.07quint(5.5); 28.69 
CH2(3,11) -  3.75-3.83m; 68.76 
CH2-O - 3.70-3.81m ; 70.58 
CH2-O - 3.67-3.72m ; 70.69 
cis-3 (12) 
 
 
69.69 
65.66 
4.36dd(9.0; 1.5); 3.78d(9.0); 67.33 
4.28dd(9.5; 1.5); 3.61d(9.5); 69.11 
 
CH2(1,13) - 2.81dt(12.0; 6.0); 3.25dt( 12.0; 7.0); 
50.06 
CH2(2,12) – 1.99-2.11m; 28.40 
CH2(3,11) - 3.84-3.90m; 3.70dt(10; 5.5); 68.29 
CH2-O - 3.77-3.85m; 70.58 
CH2-O - 3.75-3.81m; 71.09 
eq (13) 
 
 
70.75(2C) 
70.32(1C) 
69.98(1C) 
4.42dd(9.0; 1.0); 3.80dd(9.0; 1.0); 
67.27 
4.11s; 68.24;  
4.04s; 66.70 
CH2(1) - 3.08t(6.0),50.22; CH2(13)- 3.10t (6.0), 50.75 
CH2(2) - 1.98quint(6.0), 28.47; CH2(12) -2.04quint 
(6.0), 29.22  
CH2(3) - 3.81-3.77m; 68.97; CH2(11) – 3.78t(6.0), 
68.56 
CH2-O - 3.64-3.61m; 70.54; CH2-O - 3.51-3.48m; 
70.27 
CH2-O - 3.53dd(7.5; 6.0); 69.83;CH2-O - 3.68dd(7.0; 
6.5); 69.63 
Bis-C60 
(14) 
70.58 4.41s; 67.89 CH2(1,13) - 3.21t(7.0); 51.64 
CH2(2,12) - 2.23quint(6.5); 29.12 
CH2(3,11) - 3.86t(6.5); 69.31 
CH2-O - 3.77br s; 70.80, 70.50 
δ range 65-71 3.30-5.40 
65-69 
Dioxa-C10:    CH2(1) → 52.28-52.91  
                       CH2(2) → 68.63-71.88  
                       CH2(4) → 69.46-70.71  
Trioxa-C13:   CH2(1) → 50.06-52.47 
                       CH2(2) → 28.40-29.22 
                       CH2(3) → 68.29-69.34 
                       CH2(5,6) → 69-71 
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7. Figures S1-S51 NMR and HR-M spectra of compounds 3-14 
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Fig.S1 1H NMR spectrum of compound 3 
 
 
Fig.S2 13C NMR spectrum of compound 3 
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Fig. S3 HR-MS spectrum of compound 3 
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Fig.S4 1H NMR spectrum of compound 4 
 
 
Fig.S5 13C NMR spectrum of compound 4 
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Fig. S6 HR-MS spectrum of compound 4 
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Fig.S7 1H NMR spectrum of compound 5 
 
 
Fig.S8 13C NMR spectrum of compound 5 
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Fig. S9 HR-MS spectrum of compound 5 
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Fig.S10 1H NMR spectrum of compound 6 
 
Fig.S11 13C NMR spectrum of compound 6 
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Fig S12 HR-MS spectrum of compound 6 
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Fig.S13 1H NMR spectrum of compound 7 
 
 
Fig.S14 13C NMR spectrum of compound 7 
 19
 
 
Fig S15 COSY spectrum of compound 7 
 
 
 
 
Fig S16 HSQC spectrum of compound 7 
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Fig. S17 HR-MS spectrum of compound 7 
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Fig.S18 1H NMR spectrum of compound 8 
 
 
Fig.S19 13C NMR spectrum of compound 8 
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Fig. S20 COSY spectrum of compound 8 
 
 
Fig. S21 HSQC spectrum of compound 8 
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Fig. S22 HR-MS spectrum of compound 8 
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Fig.S23 1H NMR spectrum of compound 9 
 
Fig.S24 13C NMR spectrum of compound 9 
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Fig. S25 COSY spectrum of compound 9 
 
 
 
Fig. S26 HSQC spectrum of compound 9 
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Fig. S27 HR-MS spectrum of compound 9 
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Fig.S28 1H NMR spectrum of compound 10 
 
Fig.S29 13C NMR spectrum of compound 10 
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Fig. S30 COSY spectrum of compound 10 
 
 
 
Fig. S31 HSQC spectrum of compound 10 
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Fig. S32 HR-MS spectrum of compound 10 
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Fig.S33 1H NMR spectrum of compound 11 
 
Fig.S34 13C NMR spectrum of compound 11 
 31
 
 
 
 
Fig. S35 COSY spectrum of compound 11 
 
 
Fig. S36 HSQC spectrum of compound 11 
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Fig. S37 HR-MS spectrum of compound 11 
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Fig.S38 1H NMR spectrum of compound 12 
 
Fig.S39 13C NMR spectrum of compound 12 
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Fig. S40 COSY spectrum of compound 12 
 
 
Fig. S41 HSQC spectrum of compound 12 
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Fig. S42 HR-MS spectrum of compound 12 
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Fig.S43 1H NMR spectrum of compound 13 
 
Fig.S44 13C NMR spectrum of compound 13 
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Fig. S44 COSY spectrum of compound 13 
 
 
 
Fig. S45 HSQC spectrum of compound 13 
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Fig. S46 HR-MS spectrum of compound 13 
 
 
 39
 
 
Fig.S47 1H NMR spectrum of compound 14 
 
Fig.S48 13C NMR spectrum of compound 14 
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Fig. S49 COSY spectrum of compound 14 
 
Fig. S50 HSQC spectrum of compound 14 
 41
 
 
 
 
Fig. S51 HR-MS spectrum of compound 14 
 42
 
 
Fig. S52. Representative SEM images of samples prepared from 0.5 mM solution of three regioisomeric bisadducts with the 
dioxaoctane bridge in A) ODCB; B) PhMe; C) PhMe/iPrOH 1:1; D) PhMe/dioksan 1:1 and E) CHCl3, on glass substrate at 
room temperature. 
 
 
 
 
 
 
 
 
 43
 
 
Fig. S53 Representative SEM images of samples prepared from 0.5 mM solutions of regioisomeric bisadducts with the 
trioxatridecane bridge in A) ODCB; B) PhMe; C) PhMe/i-PrOH 1:1; D) PhMe/dioxane 1:1, and E) CHCl3 on glass substrate 
at room temperature. 
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Fig. S54: CVs of compounds 7-19 in ODCB/DMF 2:1, with 0,1 M TBAP as a supporting electrolyte, recorded at the scanning rate 
of 0.7 V/s, at the room temperature, under the argon atmosphere. 
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Fig. S55: CVs of compounds 7-13 in DCM, with 0,1 M TBAP as a supporting electrolyte, recorded at the scanning rate of 0.7 V/s, 
at the room temperature under the argon atmosphere.
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Fig. S56. HPTLC of bisadduct 7. 
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Fig. S57. HPTLC of bisadduct 8. 
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Fig. S58. HPTLC of bisadduct 9. 
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Fig. S59. HPTLC of bisadduct 10. 
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Fig. S60. HPTLC of bisadduct 11. 
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Fig. S61. HPTLC of bisadduct 12. 
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Fig. S62. HPTLC of bisadduct 13. 
 53
 
Fig. S63. HPTLC of bisadduct 14. 
 
 
